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INTRODUCTION
Gamma glutamyltransferase (GGT), ala-
nine aminotransferase (ALT), aspartate
aminotransferase (AST), and alkaline
phosphatase (ALP) are common liver
enzymes. Abnormal serum circulating lev-
els of these enzymes may signal liver or
cholestatic damage (1). Circulating GGT
is present on the external surfaces of most
cells, particularly hepatocytes, and is used
as a biological marker of excessive alco-
hol intake (2). ALT and AST catalyze the
transfer of amino groups to generate prod-
ucts in gluconeogenesis and amino acid
metabolism (3, 4). Elevated serum levels
of these aminotransferases signal acute or
chronic liver injury (1). ALP is a hydrolase
enzyme that transports metabolites across
cell membranes, with elevated serum lev-
els commonly used in clinical practice as a
marker of liver or bony disease (1, 5).
In addition to their physiological func-
tions, a growing body of evidence indicates
that baseline serum levels of these enzymes
may be associated with the development
of a wide range of disease outcomes. Sev-
eral reports have indicated that among
these enzymes, elevated baseline levels of
GGT and ALT are each associated with
increased risk of future type-2 diabetes
mellitus (T2DM) (6, 7). Indeed, the asso-
ciations are apparent even within normal
ranges of these enzymes. There is, how-
ever, considerable uncertainty regarding
the association between AST level and risk
of T2DM. In a recent review, we synthe-
sized available prospective epidemiological
data on the association between AST and
incident T2DM (7). The pooled analyses
involving 1,912 incident T2DM cases did
not show a significant association between
AST and risk of future T2DM. In contrast,
a recently rigorously conducted prospec-
tive study involving 2,182 incident T2DM
cases, reported a multivariate adjusted rela-
tive risk (RR) of 1.16 (1.02–1.31) for T2DM
in a comparison of the highest to the low-
est quartile of baseline AST levels (8). The
association was continuous and extended
well within the normal range of AST lev-
els. This large study adds to the growing
body of evidence that like GGT and ALT,
elevated AST level may also be associated
with increased risk for T2DM.
The prospective evidence on the asso-
ciation between AST and T2DM is incon-
clusive and this may be attributed to sev-
eral reasons including: lack of adequate
power, unmeasured confounding, or even
over-adjustment for potential intermedi-
ates by previous studies. Given that lev-
els of serum liver enzymes (GGT, ALT,
and AST) (i) are strongly environmentally
and genetically correlated with one another
(9), and (ii) have shared genetic variances
(10), the evidence is suggestive of com-
mon biological pathways affecting levels of
these enzymes. There is therefore a pos-
sibility that the association between AST
level and risk of T2DM might be medi-
ated through the effects of the other liver
enzymes. The potential impact of other
liver enzymes on the AST–T2DM associ-
ation is unclear as it is uncertain whether
adjusting for such putative intermediates
is appropriate. There are indications that
further adjustment for other liver enzymes
may be responsible for the substantially
attenuated or null associations observed in
several studies. To help clarify the evidence,
we report an updated review.
METHODS
We searched MEDLINE, EMBASE, and
Web of Science electronic databases for
published studies reporting on the asso-
ciations between baseline AST levels and
incident T2DM since the date of the pre-
vious review (7). Details of the review
methodology and inclusion/exclusion cri-
teria have been reported previously (7).
Briefly, studies were only included if they
had at least 1 year of follow-up, recruited
participants from approximately general
populations (i.e., did not select participants
on the basis of pre-existing diabetes or
known liver disease), and excluded partici-
pants with marked elevations in AST levels.
Data were abstracted on several study char-
acteristics including degree of adjustment
for potential confounders (defined as “+”
when RRs were adjusted for age and/or sex;
“++” further adjustment for established
diabetes risk factors; and “+++” addi-
tional adjustment for liver enzymes). We
separately extracted estimates from mod-
els adjusting for established and potential
diabetes risk factors and models with addi-
tional adjustment for other liver enzymes.
We contacted authors of eligible studies
where the published data were insufficient,
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Adjusted for diabetes risk factors
Monami, 2008
Jiamjarasrangsi, 2008
Andre, 2005
Nannipieri, 2005
Doi, 2007
Hanley, 2004
Goessling, 2008
Nakanishi, 2004
Abbasi, 2012
Ahn, 2014
Sato, 2008
Abbasi, 2012
Schneider, 2013
Total  
Adjusted for liver enzymes
Jiamjarasrangsi, 2008
Doi, 2007
Nakanishi, 2004
Abbasi, 2012
Sato, 2008
Abbasi, 2012
Total 
Author, year of 
publication
36
48
89
94
135
148
208
276
503
548
878
924
2182
48
135
276
503
878
924
Cases
No. of
++
++
+
++
++
++
++
++
++
++
++
++
++
+++
+++
+++
+++
+++
+++
Degree of 
adjustment
1.00 (0.98, 1.02)
1.01 (0.99, 1.02)
1.29 (0.76, 2.19)
1.55 (1.05, 2.30)
1.68 (1.03, 2.73)
1.71 (1.11, 2.64)
1.63 (1.18, 2.24)
1.40 (1.00, 1.96)
1.14 (0.87, 1.51)
1.00 (0.79, 1.27)
1.41 (1.15, 1.72)
0.96 (0.81, 1.13)
1.14 (1.02, 1.26)
1.09 (1.03, 1.14)
1.01 (0.99, 1.03)
1.43 (0.85, 2.41)
0.80 (0.50, 1.28)
1.07 (0.81, 1.42)
0.97 (0.73, 1.27)
0.88 (0.74, 1.05)
1.00 (0.96, 1.05)
RR (95% CI)
1.25 .5 2.5 5
Relative risk (95% CI) top versus bottom third of AST level
FIGURE 1 | Prospective studies of aspartate aminotransferase
levels and type-2 diabetes mellitus risk, grouped according to
covariate adjustment levels. The summary estimates presented
were calculated using random-effects models; degree of
adjustment: +, adjusted for age and/sex; ++, additionally adjusted
for diabetes risk factors; +++, further adjusted for other liver
enzymes; AST, aspartate aminotransferase; bars, 95% CI; RR,
relative risk.
to provide relevant missing information.
Risk estimates were transformed to involve
comparisons between the top third and
bottom third of the study population’s
baseline distribution of AST levels. Consis-
tency of findings across studies was assessed
by standard χ2 and I 2 statistics (11). Pre-
specified sources of potential heterogene-
ity were explored by using random-effects
meta-regression. Evidence of publication
bias was assessed using Begg’s funnel plots
and Egger’s asymmetry test (12, 13). All
analyses were performed using Stata release
12 (StataCorp, College Station, TX, USA).
RESULTS
Data were available on 90,975 participants
from 13 unique prospective cohort studies
(14–24) (of which, 9 were included in the
previous review) (Table S1 in Supplemen-
tary Material). The cumulative analysis
involved 6,069 incident T2DM cases, col-
lected over average follow-up periods rang-
ing from 3 to 20 years. The pooled random-
effects RR (95% CI) for T2DM in a com-
parison of extreme thirds of AST level was
1.09 (1.03–1.14) in studies that adjusted for
potential diabetes risk factors. The corre-
sponding RR was 1.00 (0.96–1.05) in stud-
ies that additionally adjusted for other liver
enzymes (P for meta-regression= 0.05;
Figure 1). There was substantial hetero-
geneity among the studies that adjusted
for diabetes risk factors (I 2= 73%: 54–
85%, P< 0.001). The inconsistency was
to a large part explained by duration of
follow-up (P for meta-regression= 0.004),
with combined estimates from studies with
follow-up duration≥5 years (1.28, 95% CI:
1.11–1.49) being stronger than those with
shorter follow-up duration (1.02, 95% CI:
0.98–1.05). Egger’s test was not significant
(P= 0.92), consistent with observed funnel
plot symmetry.
DISCUSSION
The pattern of findings from the avail-
able evidence suggest that elevated AST is
associated with increased risk of T2DM
after controlling for potential confounding.
Stronger associations were demonstrated
for studies with longer duration of follow-
up, findings, which confirm the specula-
tive suggestion that duration of follow-up
plays a role in the association between liver
aminotransferases and T2DM (7). This
finding may, however, require replication
in further studies. The association of AST
with T2DM was, however, abrogated by
further adjustment for other liver enzymes.
These results must be interpreted with cau-
tion given potential limitations such as
effects of residual confounding, variably
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adjusted data, and the possibility for bias
when attempting to assess the impact of
putative intermediates (25) such as other
liver enzymes (GGT and ALT). If other liver
enzymes mediate the association, then cor-
rection for these enzymes may be an over-
adjustment by the studies concerned. The
relationship between these liver enzymes
and T2DM may be more complex than
generally appreciated. Future studies are
warranted to help provide insight into the
nature of these processes and determine
the joint role of these liver enzymes in the
pathophysiology of T2DM.
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